Pharmosa Biopharm Ratios and Metrics

Market cap in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2018
Period Ending	Apr '26 Apr 28, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2018
Market Capitalization	4,959	6,700	6,829	10,314	7,055	-	Upgrade
Market Cap Growth	-21.83%	-1.89%	-33.79%	46.18%	-	-	Upgrade
Enterprise Value	3,928	5,587	5,338	9,330	6,778	-	Upgrade
Last Close Price	38.40	51.90	52.90	88.00	62.22	-	Upgrade
PE Ratio	-	-	-	1219.72	-	-	Upgrade
PS Ratio	73.73	99.60	40.75	32.80	-	-	Upgrade
PB Ratio	3.18	4.30	3.52	9.07	9.27	-	Upgrade
P/TBV Ratio	3.19	4.30	3.53	9.07	9.27	-	Upgrade
P/OCF Ratio	-	-	-	327.98	-	-	Upgrade
EV/Sales Ratio	58.39	83.06	31.86	29.67	-	-	Upgrade
EV/EBITDA Ratio	-	-	-	3121.44	-	-	Upgrade
Debt / Equity Ratio	0.06	0.06	0.06	0.13	0.03	0.07	Upgrade
Debt / EBITDA Ratio	-	-	-	7.04	-	-	Upgrade
Net Debt / Equity Ratio	-0.66	-0.66	-0.77	-0.73	-0.86	-0.80	Upgrade
Net Debt / EBITDA Ratio	2.70	2.70	7.32	-277.58	2.45	1.67	Upgrade
Net Debt / FCF Ratio	2.17	2.17	5.13	16.59	2.43	1.76	Upgrade
Asset Turnover	0.03	0.03	0.10	0.30	-	-	Upgrade
Inventory Turnover	2.44	2.44	1.74	-	-	-	Upgrade
Quick Ratio	11.46	11.46	14.03	12.58	24.23	13.96	Upgrade
Current Ratio	12.11	12.11	14.48	13.02	24.65	14.39	Upgrade
Return on Equity (ROE)	-21.96%	-21.96%	-10.84%	0.89%	-41.24%	-54.73%	Upgrade
Return on Assets (ROA)	-12.87%	-12.87%	-7.81%	-0.17%	-24.49%	-28.67%	Upgrade
Return on Capital Employed (ROCE)	-24.40%	-24.40%	-10.70%	-0.20%	-35.20%	-46.80%	Upgrade
Earnings Yield	-7.74%	-5.73%	-2.44%	0.08%	-3.78%	-	Upgrade
FCF Yield	-9.60%	-7.11%	-4.28%	-0.48%	-3.81%	-	Upgrade
Buyback Yield / Dilution	-2.12%	-2.12%	-11.49%	-15.09%	-16.02%	-78.34%	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.